Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Bayer Schering and EndoCeutics form global agreement for intravaginal DHEA

May 7, 2010

Cinacalcet allows lower doses of calcitriol and phosphate for X-linked hypophosphatemia

May 6, 2010

Synageva BioPharma files for orphan drug designation for SBC-102

May 6, 2010

Corcept updates Corlux program in Cushing's syndrome

May 6, 2010

Novel parathyroid hormone secretion inhibitors claimed by Amgen

May 6, 2010

FDA grants Osiris orphan drug designation for Prochymal in type 1 diabetes

May 5, 2010

K-V Pharmaceutical provides update on confirmatory trial of Gestiva

May 5, 2010

Repros receives guidance from FDA regarding clinical hold status of Proellex

May 4, 2010

EnzymeRx reports phase I results for pegsitacase

May 3, 2010

BioMarin plans phase III trial of GALNS in MPS IVA following phase I/II results

May 3, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...